Literature DB >> 21863360

Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.

Shojiro Hata1, Yoshihiro Sakamoto, Yusuke Yamamoto, Satoshi Nara, Minoru Esaki, Kazuaki Shimada, Tomoo Kosuge.   

Abstract

BACKGROUND: Perioperative serum carbohydrate antigen 19-9 (CA 19-9) level has been reported to be a useful prognostic marker in pancreatic cancer. The object of this study was to investigate the predictive factors for survival, including preoperative and postoperative serum CA 19-9 levels in patients with pancreatic cancer.
METHODS: Between 2003 and 2009, a total of 269 patients with pancreatic invasive ductal carcinoma underwent macroscopically curative resection, and pre- and postoperative (within 3 months after surgery) serum CA 19-9 levels were evaluated in all of them. The prognostic significance of clinicopathologic factors was evaluated by univariate and multivariate analyses.
RESULTS: Preoperative serum CA 19-9 levels were higher than normal (>37 U/ml, 38-4600 U/ml) in 218 of 269 patients. Of these, after surgery, serum CA 19-9 level returned to within a normal range in 136 patients (62%), whereas 82 patients (38%) remained in the higher-than-normal range. In univariate and multivariate analyses, node metastasis (P < 0.001) and postoperative CA 19-9 level (>37 U/ml) (P < 0.0001) were independent predictors for poor survival. Postoperative CA 19-9 level was higher in patients with microscopically positive surgical margin (P = 0.02). Hepatic recurrence and peritoneal dissemination were associated with postoperative higher CA 19-9 level.
CONCLUSIONS: Postoperative CA 19-9 level was associated with positive surgical margin and hepatic or peritoneal recurrence and may be a useful predictor for survival in patients with pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21863360     DOI: 10.1245/s10434-011-2020-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.

Authors:  Ludmila Katherine Martin; Lai Wei; Elizabeth Trolli; Tanios Bekaii-Saab
Journal:  Med Oncol       Date:  2012-06-24       Impact factor: 3.064

2.  Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.

Authors:  Mitsuro Kanda; Tsutomu Fujii; Hideki Takami; Masaya Suenaga; Yoshikuni Inokawa; Suguru Yamada; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Yasuhiro Kodera
Journal:  Surg Today       Date:  2013-10-09       Impact factor: 2.549

3.  CPA4 is a promising diagnostic serum biomarker for pancreatic cancer.

Authors:  Lichao Sun; Joseph Burnett; Chunguang Guo; Yibin Xie; Jian Pan; Zhihua Yang; Yuliang Ran; Duxin Sun
Journal:  Am J Cancer Res       Date:  2015-12-15       Impact factor: 6.166

Review 4.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

5.  The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.

Authors:  Ryan M Thomas; Mark J Truty; Michael Kim; Ya'an Kang; Ran Zhang; Deyali Chatterjee; Matthew H Katz; Jason B Fleming
Journal:  Ann Surg Oncol       Date:  2014-11-18       Impact factor: 5.344

6.  Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma.

Authors:  Shutaro Hori; Kazuaki Shimada; Yoshinori Ino; Seiji Oguro; Minoru Esaki; Satoshi Nara; Yoji Kishi; Tomoo Kosuge; Yukinori Hattori; Aoi Sukeda; Yuko Kitagawa; Yae Kanai; Nobuyoshi Hiraoka
Journal:  Virchows Arch       Date:  2016-10-05       Impact factor: 4.064

7.  Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.

Authors:  Sinziana Dumitra; Mohammad H Jamal; Jad Aboukhalil; Suhail A Doi; Prosanto Chaudhury; Mazen Hassanain; Peter P Metrakos; Jeffrey S Barkun
Journal:  HPB (Oxford)       Date:  2013-03-22       Impact factor: 3.647

8.  CA 19-9 and pancreatic cancer.

Authors:  Erxi Wu; Shuang Zhou; Kruttika Bhat; Qingyong Ma
Journal:  Clin Adv Hematol Oncol       Date:  2013-01

Review 9.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

10.  Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.

Authors:  Riccardo Piagnerelli; Daniele Marrelli; Giandomenico Roviello; Francesco Ferrara; Giulio Di Mare; Costantino Voglino; Roberto Petrioli; Mario Marini; Raffaele Macchiarelli; Franco Roviello
Journal:  Tumour Biol       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.